Emmanuel Demont,
Director
Emmanuel Demont completed his PhD in France (Ecole Polytechnique, Paris), followed by a post-doc in Canada with Professor Hanessian, before moving to industrial positions in the UK, at Roche then at GSK from 2001 onwards. He has worked in multiple areas (HIV, Alzheimers, GI, inflammation) from T2L effort to candidate selection. He is currently co-leading the chemistry group of the Epigenetic DPU at GSK Stevenage and is a member of the DPU leadership team. He is accountable for the progression of all early stage programs and for the identification of clinical candidates against various epigenetic targets. He is the author of more than 70 patents and publications.
|
|
|
